HP 288 Cytokine Restraining Agent: Began a Phase I/II trial in cancer patients with advanced malignancy

Houghten Pharmaceuticals Inc.
Product: HP

Read the full 51 word article

How to gain access

Continue reading with a
two-week free trial.